Sionna Therapeutics (SION) Income from Continuing Operations (2024 - 2026)

Sionna Therapeutics has disclosed Income from Continuing Operations across 3 years of filings, most recently posting 26779000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 26779000.0, down 60.75% year-over-year; the trailing twelve-month figure through Mar 2026 was 85807000.0 (down 28.01% YoY), and the FY2025 annual result was 75687000.0, down 21.32% from the prior year.
• Income from Continuing Operations came in at 26779000.0 for Q1 2026 at Sionna Therapeutics, down from 20440000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 8726000.0 in Q2 2024 to a low of 26779000.0 in Q1 2026.
• The 3-year median for Income from Continuing Operations is 18239000.0 (2025), against an average of 18316888.89.
• Peak annual rise in Income from Continuing Operations reached 20.61% in 2025, while the deepest fall reached 109.02% in 2025.
• Sionna Therapeutics' Income from Continuing Operations stood at 16014000.0 in 2024, then fell by 27.64% to 20440000.0 in 2025, then plunged by 31.01% to 26779000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 26779000.0 (Q1 2026), 20440000.0 (Q4 2025), and 20349000.0 (Q3 2025), per Business Quant data.